Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Living in deprived neighborhoods reshapes the gut microbiome

This study reveals links between socioeconomic deprivation and gut microbiome changes, highlighting potential pathways to mental and metabolic health issues.

2 Mar 2026

Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis

Researchers analyzed over 272,000 UK Biobank participants and used Mendelian randomization to investigate whether circulating phenylalanine and tyrosine influence lifespan. Genetically predicted higher tyrosine levels were linked to shorter lifespan, particularly in men, while phenylalanine showed no independent effect after adjustment.

1 Mar 2026

Colorful japonica rice varieties show unique health-promoting lipids

Rice feeds more than half of the world's population, yet we still only partly understand the nutrients it contains.

27 Feb 2026

How physical strength and self-belief grow together in teens

Physical fitness and psychological resilience develop side by side during adolescence, a life stage that lays the foundation for adult health. Cardiorespiratory endurance, muscular strength, and agility are well-known predictors of cardiometabolic health, while self-efficacy, defined as the belief in one's ability to overcome challenges, shapes motivation, persistence, and coping strategies.

26 Feb 2026

New review explains how circular RNAs could unlock fat browning therapies

A Cell Death & Disease review synthesizes preclinical evidence that circular RNAs regulate adipose browning and metabolic pathways through microRNA interactions, protein binding, and organelle-linked stress mechanisms. It highlights their biomarker and therapeutic potential in obesity and type 2 diabetes while underscoring key translational challenges, including delivery specificity and human validation.

26 Feb 2026

Heavy alcohol intake is associated with dangerous belly fat accumulation, large UK study shows

In a large UK population cohort, higher weekly alcohol consumption was dose-dependently associated with greater visceral fat mass measured by DXA, independent of total body fat. Heavy drinkers showed over 10% higher proportional visceral fat compared with lower consumption groups, a pattern linked to increased cardiometabolic risk.

26 Feb 2026

Combining healthy lifestyle and GLP-1 therapy reduces heart risks in diabetes

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System.

25 Feb 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026

Tirzepatide activates brown fat, boosting metabolism beyond appetite control

Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years.

24 Feb 2026

Higher ultra-processed food intake aligns with greater binge eating risk in obesity study

Higher intake of ultra-processed foods in adults with obesity was associated with disordered eating symptoms, poorer diet quality, and lower protein intake. The cross-sectional findings suggest dietary processing level may influence eating behaviour patterns relevant to obesity management, though causality cannot be inferred.

23 Feb 2026

Researchers show red blood cells drive better glucose tolerance at high altitude

Chronic hypoxia improves glucose tolerance in mice through insulin-independent mechanisms, with red blood cells acting as a major systemic glucose sink. Increased erythrocyte production and altered glycolytic flux help reduce circulating glucose while supporting oxygen delivery to tissues.

22 Feb 2026

Mounjaro ingredient shows promise in lowering alcohol consumption

For the first time, researchers show that tirzepatide - the active ingredient in the diabetes and weight-loss drug Mounjaro - reduces alcohol intake as well as relapse-like behaviors in rats and mice.

20 Feb 2026

Cyborg transplants may advance cell-based therapies for diabetes

A new electronic implant system can help lab‑grown pancreatic cells mature and function properly, potentially providing a basis for novel, cell-based therapies for diabetes.

19 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Gut bacteria patterns help predict insulin resistance in type 2 diabetes, study finds

Researchers used 16S rRNA sequencing and machine learning to identify gut microbiome patterns associated with insulin resistance severity in people with type 2 diabetes. XGBoost models showed that specific bacterial genera, including Bacteroides and Faecalibacterium, help distinguish individuals with higher insulin resistance from healthy controls.

19 Feb 2026

Monthly produce prescriptions do not improve blood sugar

Findings from a study on produce prescriptions show no significant improvement in blood sugar control, emphasizing the importance of addressing food insecurity.

19 Feb 2026

Intermittent calorie restriction proves as effective as daily calorie cuts for type 2 diabetes

A post-hoc analysis of two clinical trials compared continuous calorie restriction with early time-restricted eating in adults with type 2 diabetes and overweight or obesity over three months. Both approaches improved weight, body composition, and metabolic health, with no clear superiority except for lower dropout with intermittent restriction.

18 Feb 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Lifestyle medicine practice linked to lower clinician burnout

Healthcare professionals report that treating patients with lifestyle medicine helps to reduce burnout by increasing professional satisfaction, meaning, and a sense of effectiveness at work, according to a new study published in BMC Health Services Research.

18 Feb 2026

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, inflammatory, mitochondrial, and proteostasis pathways. Evidence from mechanistic, preclinical, and early clinical studies suggests potential neuroprotective effects, but definitive disease-modifying benefit remains unproven.

17 Feb 2026